Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.

Saved in:
Bibliographic Details
Title: Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
Authors: Pu X; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China., Li J; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610000, China., Zhang B; Shanghai Chest Hospital, Jiao Tong University, Shanghai, 200025, China., Zhang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China., K Mok TS; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 999077, China., Nakagawa K; Department of Medicine, Kindai University Hospital, Osaka, 589-8511, Japan., Rosell R; Dr. Rosell Oncology Institute & Quirón-Dexeus University Institute, Barcelona, 08028, Spain., Cheng Y; Jilin Provincial Cancer Hospital, Changchun, China., Zhou X; First Affiliated Hospital of Third Military Medical University, Chongqing, 400038, China., Miglorino MR; Pneumological Oncology, San Camillo Forlanini Hospital, Roma, 00152, Italy., Niho S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 2778577, Japan., Lee KH; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, 28644, South Korea., Corral J; Clínica Universidad de Navarra, Madrid, 28027, Spain., Pluzanski A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-034, Poland., Li J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China., Linke R; SFJ Pharmaceuticals Inc., Pleasanton, CA 94588, USA., Pan F; Pfizer, Beijing, 100010, China., Tang Y; Pfizer, San Diego, CA 92121, USA., Tan W; Pfizer, San Diego, CA 92121, USA., Wu L; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Source: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (37), pp. 2971-2982. Date of Electronic Publication: 2024 Oct 03.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8301
DOI:10.1080/14796694.2024.2404762